Visit the original URL
36 Krypton learned that, according to the official website of the State Food and Drug Administration, on December 29, the State Food and Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the “Drug Administration Law” and in accordance with the special drug approval procedures, and conditionally approved Merck’s new coronavirus treatment drug Monogravir capsules (trade name: LAGEVRIO) import registration. This product is an oral small-molecule novel coronavirus treatment drug, which is used to treat adults with mild to moderate novel coronavirus infection (COVID-19) patients with high risk factors for severe disease, such as advanced age, obesity or overweight, chronic kidney disease Patients with severe high-risk factors such as disease, diabetes, severe cardiovascular disease, chronic obstructive pulmonary disease, and active cancer. Patients should use the medicine strictly according to the instructions under the guidance of doctors. The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit follow-up research results in a timely manner.
media reports
The Paper News Interface 36Kr Titanium Media Sina IT Home
related events
- The State Food and Drug Administration approved the import registration of Merck’s new coronavirus treatment drug Monogravir Capsules with conditions2022-12-30
- State Food and Drug Administration emergency conditional approval of Pfizer’s new coronavirus treatment drug2022-02-12
- Ministry of Science and Technology: It is clear that chloroquine phosphate is effective in the treatment of new coronary pneumonia2020-02-17
This article is transferred from: https://readhub.cn/topic/8mat7QN2hjB
This site is only for collection, and the copyright belongs to the original author.